NASDAQ$JAZZ
Jazz Pharmaceuticals · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Jazz Pharmaceuticals reported Q4 2020 earnings with total revenues increasing by 14% and launched Xywav in the U.S.
Jazz Pharmaceuticals announced its Q4 2020 financial results, with total revenues increasing by 14% compared to the same period in 2019. The company highlighted the successful U.S. launches of Zepzelca and Xywav and provided full year 2021 total revenue guidance of $2.55 Billion to $2.70 Billion.
- Total revenues increased 14% in the fourth quarter of 2020 compared to the same period in 2019.
- Neuroscience net product sales in the fourth quarter of 2020 increased 6% compared to the same period in 2019, driven by the launch of Xywav.
- Oncology net product sales in the fourth quarter of 2020 increased 46% compared to the same period in 2019, led by Zepzelca net product sales.
- The company expects 2021 to be another catalyst-rich year as they focus on their ambitious set of objectives.
Headline financials
Revenue & EPS history
Jazz Pharmaceuticals · Revenue · Quarterly
$666M
Revenue by segment
Jazz Pharmaceuticals · $493M total across 4 segments · Q1 2020
- Xyrem$408M+10.7%82.8%
- Defitelio/defibrotide$47.4M+14.3%9.6%
- Vyxeos$32.7M+13.0%6.6%
- Royalties & Contract Revenue$4.52M-6.9%0.9%
Forward guidance
Jazz Pharmaceuticals provided full year 2021 financial guidance on a standalone basis and does not reflect the impact of the proposed acquisition of GW Pharmaceuticals. They plan to provide updated guidance following the close of the planned transaction.
Tailwinds
- Revenues $2,550 - $2,700 million
- Total net product sales $2,540 - $2,685 million
- Neuroscience $1,785 - $1,885 million
- Oncology $715 - $835 million
- Net income per diluted share $8.30 - $10.45
Headwinds
- SG&A expenses $1,032 - $1,100 million
- SG&A expenses as % of total revenues 38% - 43%
- R&D Expenses $365 - $410 million
- R&D expenses as % of total revenues 14% - 16%
- Effective tax rate 18% - 20%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
-0.3%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+0.7%
Avg return
30 days after
52%
34 / 65 earnings
Positive
+13.4%
Q4 2025
Best reaction
-13.4%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.1% | +8.6% | +15.4% | |
| Q4 2025 | +13.4% | +9.6% | +5.1% | |
| Q3 2025 | -2.4% | -0.1% | +23.7% | |
| Q1 2025 | -8.6% | -6.8% | -0.0% | |
| Q4 2024 | +3.2% | +0.4% | -12.0% | |
| Q3 2024 | +6.9% | +14.1% | +10.0% | |
| Q2 2024 | +1.9% | -0.6% | +3.3% | |
| Q1 2024 | -1.3% | -0.8% | -5.0% | |
| Q4 2023 | -10.1% | -11.1% | -9.0% | |
| Q3 2023 | -12.8% | -8.7% | -9.9% | |
| Q2 2023 | +2.2% | +5.9% | +3.1% | |
| Q1 2023 | +1.2% | -0.6% | -6.2% | |
| Q4 2022 | +2.8% | +1.7% | +4.2% | |
| Q3 2022 | +5.1% | +4.1% | +6.5% | |
| Q2 2022 | -1.0% | +0.9% | +1.4% | |
| Q1 2022 | -1.9% | -9.2% | -2.9% | |
| Q4 2021 | +11.4% | +12.4% | +13.3% | |
| Q3 2021 | +2.3% | +4.7% | -7.7% | |
| Q2 2021 | -10.1% | -12.1% | -20.5% | |
| Q1 2021 | +3.4% | +5.7% | +5.0% | |
| Q4 2020 | +7.3% | +3.9% | +3.1% | |
| Q3 2020 | +3.2% | +3.2% | +0.3% | |
| Q2 2020 | +9.2% | +12.6% | +20.0% | |
| Q1 2020 | +4.2% | +1.6% | +12.1% | |
| Q4 2019 | -10.9% | -12.4% | -23.0% | |
| Q3 2019 | -1.0% | +1.2% | +15.1% | |
| Q2 2019 | +0.9% | +1.4% | -6.4% | |
| Q1 2019 | +5.9% | +4.8% | -3.0% | |
| Q4 2018 | +9.2% | +10.1% | +11.0% | |
| Q3 2018 | -13.4% | -10.2% | -11.5% | |
| Q2 2018 | -0.6% | -0.3% | -4.4% | |
| Q1 2018 | +6.3% | +11.8% | +19.4% | |
| Q4 2017 | -1.8% | -4.1% | +2.4% | |
| Q3 2017 | -2.7% | -1.1% | -3.9% | |
| Q2 2017 | -8.1% | -8.3% | -3.1% | |
| Q1 2017 | +0.1% | -1.8% | -1.4% | |
| Q4 2016 | -0.9% | -2.2% | +6.4% | |
| Q3 2016 | +4.7% | +5.2% | -5.3% | |
| Q2 2016 | -6.0% | -8.4% | -18.4% | |
| Q1 2016 | +0.7% | — | — | |
| Q4 2015 | -2.9% | — | — | |
| Q3 2015 | -4.5% | — | — | |
| Q2 2015 | -3.4% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | +3.4% | — | — | |
| Q3 2014 | -1.8% | — | — | |
| Q2 2014 | +3.7% | — | — | |
| Q1 2014 | -5.8% | — | — | |
| Q4 2013 | -5.6% | — | — | |
| Q3 2013 | +3.5% | — | — | |
| Q2 2013 | +3.3% | — | — | |
| Q1 2013 | -7.1% | — | — | |
| Q4 2012 | +3.1% | — | — | |
| Q3 2012 | +0.4% | — | — | |
| Q2 2012 | -4.9% | — | — | |
| Q1 2011 | -2.4% | — | — | |
| Q1 2012 | +2.0% | — | — | |
| Q1 2010 | +3.8% | — | — | |
| Q4 2011 | +3.8% | — | — | |
| Q4 2009 | +3.8% | — | — | |
| Q3 2010 | -0.6% | — | — | |
| Q3 2011 | -0.6% | — | — | |
| Q2 2011 | -9.2% | — | — | |
| Q4 2010 | -9.2% | — | — | |
| Q2 2010 | -9.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro